Overlapping surgery—in which a surgeon moves from one procedure to the next before the first is finished, leaving junior surgeons and trainees to wrap up the noncritical portions of the surgery—isn’t associated with increased mortality or post-op complications in most cases. But, according to a study published in JAMA Feb. 26, it can raise the risk of adverse events in high-risk patients and those undergoing coronary artery bypass graft (CABG) surgery.

Two of Medtronic’s drug-eluting stents (DES)—the Resolute Onyx and the Resolute Integrity—have been granted FDA approval to treat coronary artery disease patients with chronic total occlusion (CTO), the company announced Feb. 26.

Women see worse outcomes than men after thoracic aortic surgery requiring hypothermic circulatory arrest (HCA), researchers reported in the Feb. 26 edition of Circulation.

The ultra-thin Orsiro drug-eluting stent (DES) has received FDA approval and is now commercially available in the United States, device manufacturer Biotronik announced Feb. 22.

Individuals undergoing cardiac surgery might benefit from a pre-scheduled postoperative cocktail of intravenous (IV) acetaminophen and either propofol or dexmedetomidine, according to Harvard researchers who found the common painkiller could reduce in-hospital delirium in older patients.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

Five-year survival rates and cardiovascular outcomes are similar between elderly patients who undergo both off- and on-pump coronary artery bypass grafting (CABG), according to research out of Germany.

A simple educational initiative designed to show cardiac surgeons how often they used blood transfusions—and how much they cost—helped one heart center significantly cut its rate of blood utilization and save a projected $500,000 each year.